Dividend Overview
Dividend Yield
—
Dividend / Share
—
Nektar Therapeutics
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California.
Current Price
$70.62
-4.99%Profile
Valuation (TTM)
Market Cap$2.03B
P/E-12.81
EV—
P/B22.55
Shares Out28.69M
P/Sales36.42
Revenue$55.63M
EV/EBITDA—
Nektar Therapeutics (NKTR) Dividends
Key Metrics
Market Cap
$2.03B
P/E Ratio
-12.81
Forward P/E
—
EPS
$-9.73
PEG Ratio
0.26
Book Value
$3.13
Dividend Yield
—
Profit Margin
-284.18%
ROE
-175.99%
Dividend History
Dividend Safety
NKTR Dividend Analysis
Nektar Therapeutics (NKTR) dividend analysis including yield, payout history, and sustainability metrics.
P/E ratio: -12.81. Profit margin: -284.18%. Free cash flow: $-209.38M. This page shows Nektar Therapeutics's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.
GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Nektar Therapeutics's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.